Global Transdermal Drug Delivery System

Transdermal Drug Delivery System Comprehensive Study by Type (Transdermal Patches, Transdermal Semisolids), Application (Pain Management, Neurological Disorders, Hormone Replacement Therapy, Transdermal Estrogen Therapy, Cardiovascular Diseases, Others) Players and Region - Global Market Outlook to 2026

Transdermal Drug Delivery System Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Transdermal drug delivery system is a controlled drug delivery system in which the drugs can deliver through the skin portal to systemic circulation at a predetermined rate and maintain clinically the effective concentrations over a particular time. The advantages of transdermal drug delivery system are- prolonged therapeutic effect, prolonged duration action, Uniform plasma levels, administration of the complete dose, improved bioavailability, better patient compliance and easy termination of drug therapy. It is widely used for Neurological Disorders Pain Management, Hormone Replacement Therapy, Cardiovascular Diseases, Transdermal Estrogen Therapy, and Smoking Cessation. Transdermal Drug Delivery System is mainly segmented down by Transdermal Patches which includes Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Matrix, Vapor Patch and Transdermal Semisolids that covers Ointments, Gels, Sprays, and others. Moreover, rising Prevalence of Chronic Disorders and Technological Advancements in Drug Delivery Systems anticipated for the growth of Global Transdermal Drug Delivery Systems.

Segment Analysis
AMA Research have segmented the market of Global Transdermal Drug Delivery System market by Type, Application and Region. On the basis of Type, Pain Management are dominating the market in the year 2020

On the basis of geography, the market of Transdermal Drug Delivery System has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2020.

Market Drivers
Increasing Geriatric Population, Rising Prevalence of Chronic Disorders and Technological Advancements in Drug Delivery Systems

Opportunities
Collaboration between Pharmaceutical Companies and Drug Delivery Firms and Emerging Nations

Restraints
  • Side Effects of Systems at the Site of Application


In addition to the aforementioned factor, Increasing Geriatric Population is expected to propel the growth of the market over the forecast period.

Competitive Landscape
In February 2019 Hisamitsu Pharmaceutical Co., Inc., a leader in the manufacturing of transdermal patch has signed commercialization agreement with Kyowa Hakko Kirin Co., Ltd., a Japanese pharmaceutical and biotechnology company for HP-3000 product. The product a systemic transdermal Parkinson’s disease treatment patch developed by Hisamitsu Pharmaceutical’s TDDS (Transdermal Drug Delivery System) technologies for which Kyowa Hakko Kirin will be responsible for commercialization of the product.
The key Players profiled in the study are Hisamitsu Pharmaceutical Co., Inc. (Japan), Novartis AG (Switzerland), Mylan N.V. (United States), Johnson & Johnson Services, Inc. (United States), UCB S.A. (Belgium), Endo International, Inc. (Ireland), GlaxoSmithKline PLC (United Kingdom), Boehringer Ingelheim International GmbH (Germany), Acrux Limited (Australia) and Luye Pharma Group (China). A lot of United States players are profiled in the research study indicating a strong market dependence.

Report Objectives / Segmentation Covered

By Type
  • Transdermal Patches
  • Transdermal Semisolids
By Application
  • Pain Management
  • Neurological Disorders
  • Hormone Replacement Therapy
  • Transdermal Estrogen Therapy
  • Cardiovascular Diseases
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population
      • 3.2.2. Rising Prevalence of Chronic Disorders
      • 3.2.3. Technological Advancements in Drug Delivery Systems
    • 3.3. Market Challenges
      • 3.3.1. Technical Barriers Related To Skin Irritation and Permeability
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Transdermal Drug Delivery System, by Type, Application and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Transdermal Drug Delivery System (Value)
      • 5.2.1. Global Transdermal Drug Delivery System by: Type (Value)
        • 5.2.1.1. Transdermal Patches
        • 5.2.1.2. Transdermal Semisolids
      • 5.2.2. Global Transdermal Drug Delivery System by: Application (Value)
        • 5.2.2.1. Pain Management
        • 5.2.2.2. Neurological Disorders
        • 5.2.2.3. Hormone Replacement Therapy
        • 5.2.2.4. Transdermal Estrogen Therapy
        • 5.2.2.5. Cardiovascular Diseases
        • 5.2.2.6. Others
      • 5.2.3. Global Transdermal Drug Delivery System Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Transdermal Drug Delivery System (Volume)
      • 5.3.1. Global Transdermal Drug Delivery System by: Type (Volume)
        • 5.3.1.1. Transdermal Patches
        • 5.3.1.2. Transdermal Semisolids
      • 5.3.2. Global Transdermal Drug Delivery System by: Application (Volume)
        • 5.3.2.1. Pain Management
        • 5.3.2.2. Neurological Disorders
        • 5.3.2.3. Hormone Replacement Therapy
        • 5.3.2.4. Transdermal Estrogen Therapy
        • 5.3.2.5. Cardiovascular Diseases
        • 5.3.2.6. Others
      • 5.3.3. Global Transdermal Drug Delivery System Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Transdermal Drug Delivery System (Price)
      • 5.4.1. Global Transdermal Drug Delivery System by: Type (Price)
  • 6. Transdermal Drug Delivery System: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hisamitsu Pharmaceutical Co., Inc. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan N.V. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson Services, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. UCB S.A. (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Endo International, Inc. (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Acrux Limited (Australia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Luye Pharma Group (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Transdermal Drug Delivery System Sale, by Type, Application and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Transdermal Drug Delivery System (Value)
      • 7.2.1. Global Transdermal Drug Delivery System by: Type (Value)
        • 7.2.1.1. Transdermal Patches
        • 7.2.1.2. Transdermal Semisolids
      • 7.2.2. Global Transdermal Drug Delivery System by: Application (Value)
        • 7.2.2.1. Pain Management
        • 7.2.2.2. Neurological Disorders
        • 7.2.2.3. Hormone Replacement Therapy
        • 7.2.2.4. Transdermal Estrogen Therapy
        • 7.2.2.5. Cardiovascular Diseases
        • 7.2.2.6. Others
      • 7.2.3. Global Transdermal Drug Delivery System Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Transdermal Drug Delivery System (Volume)
      • 7.3.1. Global Transdermal Drug Delivery System by: Type (Volume)
        • 7.3.1.1. Transdermal Patches
        • 7.3.1.2. Transdermal Semisolids
      • 7.3.2. Global Transdermal Drug Delivery System by: Application (Volume)
        • 7.3.2.1. Pain Management
        • 7.3.2.2. Neurological Disorders
        • 7.3.2.3. Hormone Replacement Therapy
        • 7.3.2.4. Transdermal Estrogen Therapy
        • 7.3.2.5. Cardiovascular Diseases
        • 7.3.2.6. Others
      • 7.3.3. Global Transdermal Drug Delivery System Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Transdermal Drug Delivery System (Price)
      • 7.4.1. Global Transdermal Drug Delivery System by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Transdermal Drug Delivery System: by Type(USD Million)
  • Table 2. Transdermal Drug Delivery System Transdermal Patches , by Region USD Million (2015-2020)
  • Table 3. Transdermal Drug Delivery System Transdermal Semisolids , by Region USD Million (2015-2020)
  • Table 4. Transdermal Drug Delivery System: by Application(USD Million)
  • Table 5. Transdermal Drug Delivery System Pain Management , by Region USD Million (2015-2020)
  • Table 6. Transdermal Drug Delivery System Neurological Disorders , by Region USD Million (2015-2020)
  • Table 7. Transdermal Drug Delivery System Hormone Replacement Therapy , by Region USD Million (2015-2020)
  • Table 8. Transdermal Drug Delivery System Transdermal Estrogen Therapy , by Region USD Million (2015-2020)
  • Table 9. Transdermal Drug Delivery System Cardiovascular Diseases , by Region USD Million (2015-2020)
  • Table 10. Transdermal Drug Delivery System Others , by Region USD Million (2015-2020)
  • Table 11. South America Transdermal Drug Delivery System, by Country USD Million (2015-2020)
  • Table 12. South America Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 13. South America Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 14. Brazil Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 15. Brazil Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 16. Argentina Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 17. Argentina Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 18. Rest of South America Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 19. Rest of South America Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 20. Asia Pacific Transdermal Drug Delivery System, by Country USD Million (2015-2020)
  • Table 21. Asia Pacific Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 22. Asia Pacific Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 23. China Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 24. China Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 25. Japan Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 26. Japan Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 27. India Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 28. India Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 29. South Korea Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 30. South Korea Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 31. Taiwan Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 32. Taiwan Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 33. Australia Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 34. Australia Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 35. Rest of Asia-Pacific Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 36. Rest of Asia-Pacific Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 37. Europe Transdermal Drug Delivery System, by Country USD Million (2015-2020)
  • Table 38. Europe Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 39. Europe Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 40. Germany Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 41. Germany Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 42. France Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 43. France Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 44. Italy Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 45. Italy Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 46. United Kingdom Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 47. United Kingdom Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 48. Netherlands Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 49. Netherlands Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 50. Rest of Europe Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 51. Rest of Europe Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 52. MEA Transdermal Drug Delivery System, by Country USD Million (2015-2020)
  • Table 53. MEA Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 54. MEA Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 55. Middle East Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 56. Middle East Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 57. Africa Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 58. Africa Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 59. North America Transdermal Drug Delivery System, by Country USD Million (2015-2020)
  • Table 60. North America Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 61. North America Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 62. United States Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 63. United States Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 64. Canada Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 65. Canada Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 66. Mexico Transdermal Drug Delivery System, by Type USD Million (2015-2020)
  • Table 67. Mexico Transdermal Drug Delivery System, by Application USD Million (2015-2020)
  • Table 68. Transdermal Drug Delivery System Sales: by Type(K Unit)
  • Table 69. Transdermal Drug Delivery System Sales Transdermal Patches , by Region K Unit (2015-2020)
  • Table 70. Transdermal Drug Delivery System Sales Transdermal Semisolids , by Region K Unit (2015-2020)
  • Table 71. Transdermal Drug Delivery System Sales: by Application(K Unit)
  • Table 72. Transdermal Drug Delivery System Sales Pain Management , by Region K Unit (2015-2020)
  • Table 73. Transdermal Drug Delivery System Sales Neurological Disorders , by Region K Unit (2015-2020)
  • Table 74. Transdermal Drug Delivery System Sales Hormone Replacement Therapy , by Region K Unit (2015-2020)
  • Table 75. Transdermal Drug Delivery System Sales Transdermal Estrogen Therapy , by Region K Unit (2015-2020)
  • Table 76. Transdermal Drug Delivery System Sales Cardiovascular Diseases , by Region K Unit (2015-2020)
  • Table 77. Transdermal Drug Delivery System Sales Others , by Region K Unit (2015-2020)
  • Table 78. South America Transdermal Drug Delivery System Sales, by Country K Unit (2015-2020)
  • Table 79. South America Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 80. South America Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 81. Brazil Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 82. Brazil Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 83. Argentina Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 84. Argentina Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 85. Rest of South America Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 86. Rest of South America Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 87. Asia Pacific Transdermal Drug Delivery System Sales, by Country K Unit (2015-2020)
  • Table 88. Asia Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 89. Asia Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 90. China Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 91. China Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 92. Japan Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 93. Japan Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 94. India Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 95. India Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 96. South Korea Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 97. South Korea Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 98. Taiwan Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 99. Taiwan Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 100. Australia Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 101. Australia Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 102. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 103. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 104. Europe Transdermal Drug Delivery System Sales, by Country K Unit (2015-2020)
  • Table 105. Europe Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 106. Europe Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 107. Germany Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 108. Germany Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 109. France Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 110. France Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 111. Italy Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 112. Italy Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 113. United Kingdom Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 114. United Kingdom Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 115. Netherlands Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 116. Netherlands Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 117. Rest of Europe Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 118. Rest of Europe Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 119. MEA Transdermal Drug Delivery System Sales, by Country K Unit (2015-2020)
  • Table 120. MEA Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 121. MEA Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 122. Middle East Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 123. Middle East Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 124. Africa Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 125. Africa Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 126. North America Transdermal Drug Delivery System Sales, by Country K Unit (2015-2020)
  • Table 127. North America Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 128. North America Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 129. United States Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 130. United States Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 131. Canada Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 132. Canada Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 133. Mexico Transdermal Drug Delivery System Sales, by Type K Unit (2015-2020)
  • Table 134. Mexico Transdermal Drug Delivery System Sales, by Application K Unit (2015-2020)
  • Table 135. Transdermal Drug Delivery System: by Type(USD/Units)
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Transdermal Drug Delivery System: by Type(USD Million)
  • Table 147. Transdermal Drug Delivery System Transdermal Patches , by Region USD Million (2021-2026)
  • Table 148. Transdermal Drug Delivery System Transdermal Semisolids , by Region USD Million (2021-2026)
  • Table 149. Transdermal Drug Delivery System: by Application(USD Million)
  • Table 150. Transdermal Drug Delivery System Pain Management , by Region USD Million (2021-2026)
  • Table 151. Transdermal Drug Delivery System Neurological Disorders , by Region USD Million (2021-2026)
  • Table 152. Transdermal Drug Delivery System Hormone Replacement Therapy , by Region USD Million (2021-2026)
  • Table 153. Transdermal Drug Delivery System Transdermal Estrogen Therapy , by Region USD Million (2021-2026)
  • Table 154. Transdermal Drug Delivery System Cardiovascular Diseases , by Region USD Million (2021-2026)
  • Table 155. Transdermal Drug Delivery System Others , by Region USD Million (2021-2026)
  • Table 156. South America Transdermal Drug Delivery System, by Country USD Million (2021-2026)
  • Table 157. South America Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 158. South America Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 159. Brazil Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 160. Brazil Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 161. Argentina Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 162. Argentina Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 163. Rest of South America Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 164. Rest of South America Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 165. Asia Pacific Transdermal Drug Delivery System, by Country USD Million (2021-2026)
  • Table 166. Asia Pacific Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 167. Asia Pacific Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 168. China Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 169. China Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 170. Japan Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 171. Japan Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 172. India Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 173. India Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 174. South Korea Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 175. South Korea Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 176. Taiwan Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 177. Taiwan Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 178. Australia Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 179. Australia Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 180. Rest of Asia-Pacific Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 181. Rest of Asia-Pacific Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 182. Europe Transdermal Drug Delivery System, by Country USD Million (2021-2026)
  • Table 183. Europe Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 184. Europe Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 185. Germany Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 186. Germany Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 187. France Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 188. France Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 189. Italy Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 190. Italy Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 191. United Kingdom Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 192. United Kingdom Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 193. Netherlands Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 194. Netherlands Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 195. Rest of Europe Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 196. Rest of Europe Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 197. MEA Transdermal Drug Delivery System, by Country USD Million (2021-2026)
  • Table 198. MEA Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 199. MEA Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 200. Middle East Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 201. Middle East Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 202. Africa Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 203. Africa Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 204. North America Transdermal Drug Delivery System, by Country USD Million (2021-2026)
  • Table 205. North America Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 206. North America Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 207. United States Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 208. United States Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 209. Canada Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 210. Canada Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 211. Mexico Transdermal Drug Delivery System, by Type USD Million (2021-2026)
  • Table 212. Mexico Transdermal Drug Delivery System, by Application USD Million (2021-2026)
  • Table 213. Transdermal Drug Delivery System Sales: by Type(K Unit)
  • Table 214. Transdermal Drug Delivery System Sales Transdermal Patches , by Region K Unit (2021-2026)
  • Table 215. Transdermal Drug Delivery System Sales Transdermal Semisolids , by Region K Unit (2021-2026)
  • Table 216. Transdermal Drug Delivery System Sales: by Application(K Unit)
  • Table 217. Transdermal Drug Delivery System Sales Pain Management , by Region K Unit (2021-2026)
  • Table 218. Transdermal Drug Delivery System Sales Neurological Disorders , by Region K Unit (2021-2026)
  • Table 219. Transdermal Drug Delivery System Sales Hormone Replacement Therapy , by Region K Unit (2021-2026)
  • Table 220. Transdermal Drug Delivery System Sales Transdermal Estrogen Therapy , by Region K Unit (2021-2026)
  • Table 221. Transdermal Drug Delivery System Sales Cardiovascular Diseases , by Region K Unit (2021-2026)
  • Table 222. Transdermal Drug Delivery System Sales Others , by Region K Unit (2021-2026)
  • Table 223. South America Transdermal Drug Delivery System Sales, by Country K Unit (2021-2026)
  • Table 224. South America Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 225. South America Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 226. Brazil Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 227. Brazil Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 228. Argentina Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 229. Argentina Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 230. Rest of South America Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 231. Rest of South America Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 232. Asia Pacific Transdermal Drug Delivery System Sales, by Country K Unit (2021-2026)
  • Table 233. Asia Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 234. Asia Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 235. China Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 236. China Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 237. Japan Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 238. Japan Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 239. India Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 240. India Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 241. South Korea Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 242. South Korea Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 243. Taiwan Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 244. Taiwan Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 245. Australia Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 246. Australia Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 247. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 248. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 249. Europe Transdermal Drug Delivery System Sales, by Country K Unit (2021-2026)
  • Table 250. Europe Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 251. Europe Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 252. Germany Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 253. Germany Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 254. France Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 255. France Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 256. Italy Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 257. Italy Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 258. United Kingdom Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 259. United Kingdom Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 260. Netherlands Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 261. Netherlands Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 262. Rest of Europe Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 263. Rest of Europe Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 264. MEA Transdermal Drug Delivery System Sales, by Country K Unit (2021-2026)
  • Table 265. MEA Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 266. MEA Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 267. Middle East Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 268. Middle East Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 269. Africa Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 270. Africa Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 271. North America Transdermal Drug Delivery System Sales, by Country K Unit (2021-2026)
  • Table 272. North America Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 273. North America Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 274. United States Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 275. United States Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 276. Canada Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 277. Canada Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 278. Mexico Transdermal Drug Delivery System Sales, by Type K Unit (2021-2026)
  • Table 279. Mexico Transdermal Drug Delivery System Sales, by Application K Unit (2021-2026)
  • Table 280. Transdermal Drug Delivery System: by Type(USD/Units)
  • Table 281. Research Programs/Design for This Report
  • Table 282. Key Data Information from Secondary Sources
  • Table 283. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Transdermal Drug Delivery System: by Type USD Million (2015-2020)
  • Figure 5. Global Transdermal Drug Delivery System: by Application USD Million (2015-2020)
  • Figure 6. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 7. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 8. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 9. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 10. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 11. Global Transdermal Drug Delivery System: by Type K Unit (2015-2020)
  • Figure 12. Global Transdermal Drug Delivery System: by Application K Unit (2015-2020)
  • Figure 13. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 14. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 15. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 16. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 17. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 18. Global Transdermal Drug Delivery System: by Type USD/Units (2015-2020)
  • Figure 19. Global Transdermal Drug Delivery System share by Players 2020 (%)
  • Figure 20. Global Transdermal Drug Delivery System share by Players (Top 3) 2020(%)
  • Figure 21. Global Transdermal Drug Delivery System share by Players (Top 5) 2020(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue: by Geography 2020
  • Figure 25. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 27. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 29. Johnson & Johnson Services, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson Services, Inc. (United States) Revenue: by Geography 2020
  • Figure 31. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
  • Figure 32. UCB S.A. (Belgium) Revenue: by Geography 2020
  • Figure 33. Endo International, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 34. Endo International, Inc. (Ireland) Revenue: by Geography 2020
  • Figure 35. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 37. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2020
  • Figure 39. Acrux Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 40. Acrux Limited (Australia) Revenue: by Geography 2020
  • Figure 41. Luye Pharma Group (China) Revenue, Net Income and Gross profit
  • Figure 42. Luye Pharma Group (China) Revenue: by Geography 2020
  • Figure 43. Global Transdermal Drug Delivery System: by Type USD Million (2021-2026)
  • Figure 44. Global Transdermal Drug Delivery System: by Application USD Million (2021-2026)
  • Figure 45. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 46. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 47. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 48. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 49. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 50. Global Transdermal Drug Delivery System: by Type K Unit (2021-2026)
  • Figure 51. Global Transdermal Drug Delivery System: by Application K Unit (2021-2026)
  • Figure 52. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 53. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 54. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 55. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 56. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 57. Global Transdermal Drug Delivery System: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Novartis AG (Switzerland)
  • Mylan N.V. (United States)
  • Johnson & Johnson Services, Inc. (United States)
  • UCB S.A. (Belgium)
  • Endo International, Inc. (Ireland)
  • GlaxoSmithKline PLC (United Kingdom)
  • Boehringer Ingelheim International GmbH (Germany)
  • Acrux Limited (Australia)
  • Luye Pharma Group (China)
Additional players considered in the study are as follows:
BRISTOL-MYERS SQUIBB COMPANY (United States) , Purdue Pharma L.P. (United States) , ECHO THERAPEUTICS, INC. (United States) , Lavipharm (Greece) , 3M (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 238 Pages 51 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Transdermal Drug Delivery System Quantitative research analysis
Global Transdermal Drug Delivery System Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Transdermal Drug Delivery System market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Transdermal Drug Delivery System market are Hisamitsu Pharmaceutical Co., Inc. (Japan), Novartis AG (Switzerland), Mylan N.V. (United States), Johnson & Johnson Services, Inc. (United States), UCB S.A. (Belgium), Endo International, Inc. (Ireland), GlaxoSmithKline PLC (United Kingdom), Boehringer Ingelheim International GmbH (Germany), Acrux Limited (Australia) and Luye Pharma Group (China), to name a few.
Pain Management is dominating segment of Transdermal Drug Delivery System Market in 2020.

Know More About Global Transdermal Drug Delivery System Report?

Have a Query? Click Here

Other Related Reports

Liquid Bandage Comprehensive Study by Type (Skin Protectants, Tissue Adhesives), Application (Humans, Animals), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Player...
$ 3500
Migraine Drugs Comprehensive Study by Type (Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}, Preventive Medications {Cardiovascular Drugs, Ant...
$ 3750
Dental Bone Graft Substitutes Comprehensive Study by Type (Synthetic Bone Grafts, Alloplast, Allograft, Xenograft), Application (Sinus Lift, Ridge Augmentation, Socket Preservation), Distribution Cha...
$ 3450
DHA Powder Comprehensive Study by Type (Alage DHA Powder, Fish Oil DHA Powder, Others), Application (Infant Formula, Dietary Supplements, Food and Beverage, Others), Distribution Channel (Online, Off...
$ 3500
Podophyllin Comprehensive Study by Type (Less than 20 % Concentration of Podophyllin, 20%-50 % Concentration of Podophyllin, More than 50 % Concentration of Podophyllin), Application (Tincture, Crea...
$ 3450
Yeast Expression Vector Comprehensive Study by Type (K. Lactis Expression Vectors, Pichia Pastoris Expression Vectors, Saccharomyces Cerevisiae Expression Vectors, Others), Application (Therapeutic, ...
$ 3450